IQVIA Holdings Inc. (IQV)

US — Healthcare Sector
Peers: RMD  A  ALC  MTD  HUM  GEHC  CAH  WAT  ILMN  HLN 

Automate Your Wheel Strategy on IQV

With Tiblio's Option Bot, you can configure your own wheel strategy including IQV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IQV
  • Rev/Share 93.443
  • Book/Share 36.9448
  • PB 5.8865
  • Debt/Equity 2.4659
  • CurrentRatio 0.7028
  • ROIC 0.0787

 

  • MktCap 36281053397.0
  • FreeCF/Share 15.5112
  • PFCF 13.7428
  • PE 28.2628
  • Debt/Assets 0.5288
  • DivYield 0
  • ROE 0.214

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 4
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade IQV TD Cowen Buy Hold -- $215 Nov. 3, 2025
Upgrade IQV Robert W. Baird Neutral Outperform -- $258 Oct. 29, 2025
Upgrade IQV HSBC Securities Hold Buy -- $235 Oct. 9, 2025
Upgrade IQV Jefferies Hold Buy -- $225 Sept. 9, 2025
Downgrade IQV HSBC Securities Buy Hold -- $160 April 25, 2025
Downgrade IQV Barclays Overweight Equal Weight -- $170 April 10, 2025
Downgrade IQV BTIG Research Buy Neutral -- -- Feb. 3, 2025
Initiation IQV Stephens -- Overweight -- $250 Dec. 20, 2024
Initiation IQV Redburn Atlantic -- Buy -- -- Oct. 14, 2024

News

IQVIA (IQV) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
IQV
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral

Evaluate the expected performance of IQVIA (IQV) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Read More
image for news IQVIA (IQV) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
IQVIA (IQV) Moves 8.7% Higher: Will This Strength Last?
IQV
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive

IQVIA (IQV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Read More
image for news IQVIA (IQV) Moves 8.7% Higher: Will This Strength Last?
Here's Why Investors Must Hold IQV Stock in Their Portfolios Now
IQV
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Positive

The IQV stock is benefiting from partner retention, acquisition and investment in AI-led innovation.

Read More
image for news Here's Why Investors Must Hold IQV Stock in Their Portfolios Now
IQVIA Gains From Diversified Client Base Despite Low Liquidity Woes
IQV
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Positive

The IQV stock benefits from its healthcare-centric IT infrastructure across the globe and a treasure trove of data distinguishing it from its competitors.

Read More
image for news IQVIA Gains From Diversified Client Base Despite Low Liquidity Woes
IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy?
IQV
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy?
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight
DXCM, ILMN, IQV, NVDA
Published: February 18, 2025 by: Zacks Investment Research
Sentiment: Neutral

ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.

Read More
image for news NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight

About IQVIA Holdings Inc. (IQV)

  • IPO Date 2013-05-09
  • Website https://www.iqvia.com
  • Industry Medical - Diagnostics & Research
  • CEO Ari Bousbib
  • Employees 89000

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.